Drugs / MP0533
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05673057 | Dec 2022 → May 2026 | leukemia, myeloid neoplasm | Molecular Partners AG | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 10
| Date | Issuer | Release |
|---|---|---|
| 2025-11-03 | Molecular Partners AG | Results Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting molecularpartners.com ↗
MP0533 shows an acceptable safety profile across DR 1–9. |
| 2025-06-11 | Molecular Partners AG | Results Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025 molecularpartners.com ↗
Data from cohort 8 show that 3 of 8 evaluable patients (> 30%) achieved a clinical response after the first cycle, with one patient achieving a complete response and two patients a complete response with partial hematologic recovery as best overall response. |
| 2025-05-15 | Molecular Partners AG | Results Molecular Partners Reports Financial Results and Highlights from Q1 2025 molecularpartners.com ↗
Initial data from cohort 8, with an additional dosing point in the step-up dosing, indicate increased rates and depth of responses, while the fully amended dosing scheme is being tested in cohort 9. |
| 2025-01-12 | Molecular Partners AG | Results Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference molecularpartners.com ↗
MP0533 clinical data show improved response rate and depth in cohort 8 with steeper step-up and more frequent dosing; additional dose densification planned in cohort 9, updates expected in 2025 |
| 2024-12-08 | Molecular Partners AG | Results Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024 molecularpartners.com ↗ |
| 2024-11-05 | Molecular Partners AG | Results Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition molecularpartners.com ↗
Clinical update from ongoing MP0533 phase 1/2a dose escalation study confirms overall acceptable safety profile observed so far and initial antileukemic and pharmacodynamic activity |
| 2024-04-29 | Molecular Partners AG | Results Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action molecularpartners.com ↗
Preclinical data of tetra-specific T cell engager MP0533 demonstrate preferential T cell mediated killing of AML cells, while sparing healthy cells |
| 2023-12-10 | Molecular Partners AG | Results Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting molecularpartners.com ↗
These data, which highlight encouraging initial safety and antitumor activity, expand upon those previously disclosed in the conference abstract. |
| 2023-11-02 | Molecular Partners AG | Results Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition molecularpartners.com ↗
The preliminary data reported indicate an acceptable safety profile, with no dose-limiting toxicity or Grade ≥3 adverse reactions. |
| 2022-12-12 | Molecular Partners AG | Results Molecular Partners Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML molecularpartners.com ↗
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, presented today new preclinical data showing its DARPin T-cell engager MP0533 can induce preferential killing of cells expressing two or three tumor-associated antigens (TAAs) compared to cells expressing a single TAA. |
All press releases naming this drug 16 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MP0533 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05673057 ↗ |
| Action | Deplete | “aiming to enable avidity-driven T cell-mediated killing of AML cells” PMID 38683145 ↗ Jul 2024 |
| Modality | Protein / enzyme biologic | “multispecific CD3-engaging designed ankyrin repeat protein (DARPin)” PMID 38683145 ↗ Jul 2024 |
| Route | Intravenous | “MP0533 is administered by intravenous infusion” NCT05673057 ↗ |